🇺🇸 FDA
Patent

US 10022367

Sustained-release buprenorphine solutions

granted A61KA61K31/485A61K47/10

Quick answer

US patent 10022367 (Sustained-release buprenorphine solutions) held by Indivior UK Limited expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Indivior UK Limited
Grant date
Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
49
CPC classes
A61K, A61K31/485, A61K47/10, A61K47/22, A61K9/0019